SIRT1 activator. Inhibits proliferation of breast cancer cell lines expressing mutant p53. Induces G2/M cell cycle arrest and apoptosis in triple negative breast cancer cells (TNBCs) in vitro.
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 372.18. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.69 mL||13.43 mL||26.87 mL|
|5 mM||0.54 mL||2.69 mL||5.37 mL|
|10 mM||0.27 mL||1.34 mL||2.69 mL|
|50 mM||0.05 mL||0.27 mL||0.54 mL|
The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.
References are publications that support the products' biological activity.
Yi et al (2013) Targeting mutant p53 by a SIRT1 activator YK-3-237 inhibits the proliferation of triple-negative breast cancer cells. Oncotarget 4 984 PMID: 23846322
Ponnusamy et al (2015) Activation of sirtuin-1 promotes renal fibroblast activation and aggravates renal fibrogenesis. J.Pharmacol.Exp.Ther 354 142 PMID: 26022003
If you know of a relevant reference for YK 3-237, please let us know.
View Related Products by Product Action
Keywords: YK3-237 SIRT1 sirtuins activators activates deacetylases antiproliferative Sir2-like Family Deacetylases
Citations for YK 3-237
Citations are publications that use Tocris products.
Currently there are no citations for YK 3-237. Do you know of a great paper that uses YK 3-237 from Tocris? If so please let us know.